TELA Bio 

$2.64
7
+$0+0% Wednesday 20:00

统计数据

当日最高
-
当日最低
-
52周最高
-
52周最低
-
成交量
-
平均成交量
-
市值
71.67M
市盈率
-
股息收益率
-
股息
-

即将到来

收益

6Nov预期
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一个
-0.63
-0.5
-0.36
-0.23
预期每股收益
-0.40592
实际每股收益
N/A

人们还关注

此列表基于关注TELA的Stock Events用户的观察列表。这不是投资建议。

竞争者

这个列表是基于最近市场事件的分析。这不是投资建议。

分析师评级

10$平均价格目标
最高估值为 $12。
来自过去6个月内的 4 个评级。这不是投资建议。
买入
75%
持有
25%
卖出
0%

关于

Health Technology
Medical Specialties
Manufacturing
Surgical and Medical Instrument Manufacturing
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Show more...
首席执行官
员工
227
国家
US
ISIN
US8723811084

上市公司